MTOR and neoplasm: Often mutated in various cancers, PI3K triggers the PI3K/Akt/mTOR pathway, reducing the effectiveness of T-cell mediated responses by suppressing the activity of tumor-specific T cells and hindering their infiltration into tumors [[140], [141], [142]].